comparemela.com

Latest Breaking News On - Peter jeffrey conn - Page 1 : comparemela.com

Karuna Therapeutics (KRTX) Neutral Rating Reiterated at Cantor Fitzgerald

Karuna Therapeutics (KRTX) Neutral Rating Reiterated at Cantor Fitzgerald
themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.

Karuna Therapeutics (NASDAQ:KRTX) Now Covered by Wells Fargo & Company

Wells Fargo & Company initiated coverage on shares of Karuna Therapeutics (NASDAQ:KRTX – Free Report) in a research report sent to investors on Tuesday, Marketbeat reports. The brokerage issued an overweight rating and a $225.00 price target on the stock. A number of other research analysts have also recently commented on the stock. JPMorgan Chase […]

Karuna Therapeutics (NASDAQ:KRTX) PT Lowered to $235 00 at Royal Bank of Canada

Karuna Therapeutics (NASDAQ:KRTX – Free Report) had its price objective decreased by Royal Bank of Canada from $249.00 to $235.00 in a research note published on Friday, Benzinga reports. Royal Bank of Canada currently has an outperform rating on the stock. Several other equities analysts have also recently weighed in on the stock. Morgan Stanley […]

Royal Bank of Canada Cuts Karuna Therapeutics (NASDAQ:KRTX) Price Target to $235 00

Karuna Therapeutics (NASDAQ:KRTX – Free Report) had its target price cut by Royal Bank of Canada from $249.00 to $235.00 in a research report report published on Friday morning, Benzinga reports. They currently have an outperform rating on the stock. KRTX has been the subject of a number of other research reports. HC Wainwright reaffirmed […]

FY2025 EPS Estimates for Karuna Therapeutics, Inc (NASDAQ:KRTX) Lowered by Analyst

Karuna Therapeutics, Inc. (NASDAQ:KRTX – Get Rating) – Investment analysts at Zacks Research lowered their FY2025 EPS estimates for Karuna Therapeutics in a research note issued on Thursday, June 15th. Zacks Research analyst S. Ganoria now forecasts that the company will earn ($5.07) per share for the year, down from their previous forecast of ($4.81). […]

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.